SCHEMBL9520082

SCHEMBL9520082

Nc1ccc(-c2nc3ccccc3n2O)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.71
RAB9A P51151 6/20 0.71
NPC1 O15118 5/20 0.71
KMT2A Q03164 4/20 0.71
LMNA P02545 3/20 0.71
MEN1 O00255 3/20 0.71
ALDH1A1 P00352 4/20 0.66
HSD17B10 Q99714 3/20 0.66
GAA P10253 2/20 0.66
TP53 P04637 2/20 0.66
PKM P14618 2/20 0.66
ALOX15 P16050 1/20 0.66
HPGD P15428 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.56
MAPT P10636 2/20 0.56
RAD51 Q06609 1/20 0.54
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HTT P42858 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1284437 0.85 KDM4E (0.74) KDM4ERAB9ANPC1KMT2ALMNA
SCHEMBL29475390 0.85 KDM4E (0.74) KDM4ERAB9ANPC1KMT2ALMNA
SCHEMBL12325283 0.83 KMT2A (1.00) KDM4ERAB9ANPC1KMT2ALMNA
SCHEMBL6439288 0.81 ALDH1A1 (0.68) KDM4ERAB9ANPC1KMT2ALMNA
SCHEMBL9705114 0.79 ALDH1A1 (1.00) KDM4ERAB9ANPC1KMT2ALMNA
SCHEMBL31474745 0.79 ALDH1A1 (1.00) KDM4ERAB9ANPC1KMT2ALMNA
SCHEMBL16509296 0.79 KDM4E (0.50) KDM4ERAB9ANPC1KMT2ALMNA
SCHEMBL12325734 0.79 KDM4E (0.65) KDM4ERAB9ANPC1KMT2ALMNA
SCHEMBL28392218 0.79 KDM4E (0.65) KDM4ERAB9ANPC1KMT2ALMNA
SCHEMBL5702588 0.78 KDM4E (0.64) KDM4ERAB9ANPC1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-5025140-A None JP disclosed
US-20090170812-A1 Transcription factor modulating compounds and methods of use thereof PARATEK PHARMACEUTICALS, INC. (US) 2009-07-02 US disclosed
JP-H0525140-A BENZIMIDAZOLE DERIVATIVE SANKYO CO LTD 1993-02-02 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170812-A1 Transcription factor modulating compounds and methods of use thereof JUN, CREBBP, TFEB KDM4E 360/4885RAB9A 4067/4885NPC1 3055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.